EVOO for Liver Transplant Recipients
Trial Summary
What is the purpose of this trial?
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. TMAO is an attractive therapeutic target to improve vascular health and diastolic function toward preventing CVD in LT patients. Therefore, the purpose of this study is to better understand the role of TMAO in cardiovascular dysfunction patients with chronic kidney disease.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment EVOO for liver transplant recipients?
Is extra virgin olive oil (EVOO) safe for humans?
Extra virgin olive oil (EVOO) is generally considered safe for human consumption and has been shown to have antioxidant properties that may protect the liver. Studies in animals suggest it can reduce liver fat and improve insulin sensitivity, although it may not alleviate liver inflammation or fibrosis.26789
How does extra virgin olive oil (EVOO) treatment differ from other treatments for liver transplant recipients?
Extra virgin olive oil (EVOO) is unique because it has strong antioxidant properties that help protect the liver from oxidative stress, which is damage caused by free radicals. Unlike other treatments, EVOO contains high levels of phenolic compounds, such as hydroxytyrosol, which may contribute to its protective effects on the liver.6791011
Research Team
Danielle Kirkman, PhD
Principal Investigator
Virginia Commonwealth University
Eligibility Criteria
This trial is for adults over 18 who speak and understand English and have received a liver transplant. It aims to explore cardiovascular health in these patients.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dietary supplementation with 50g/day of Extra Virgin Olive Oil (EVOO) or standard of care
Follow-up
Participants are monitored for changes in frailty, diastolic function, arterial hemodynamics, microvascular function, conduit artery endothelial function, serum TMAO levels, and quality of life
Treatment Details
Interventions
- EVOO (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Commonwealth University
Lead Sponsor